Loading...

Pelin Cinar, MD, MS

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Phone--
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California Irvine, IrvineMD06/2007Doctor of Medicine
    University of California Irvine, IrvineMS06/2002Epidemiology
    University of California Irvine, IrvineBS06/2000Biological Sciences
    University of California Irvine, IrvineBA06/2000Anthropology
    University of California San Francisco, San Francisco06/2013Hematology/Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Pelin Cinar is a specialist in gastrointestinal oncology with a particular interest in pancreatic cancer. As director of quality improvement for the UCSF Helen Diller Family Comprehensive Cancer Center, she is committed to developing projects to ensure that each oncology patient at UCSF receives superior care.

    Cinar earned her medical degree and completed her residency in internal medicine at the University of California, Irvine School of Medicine. She received her fellowship training in hematology and oncology at UCSF, where she was appointed chief fellow. During her fellowship, she became passionate about quality improvement in health care and participated in efforts to improve care for oncology patients.

    In 2014, Cinar joined the faculty of the Stanford Department of Medicine as a gastrointestinal oncologist. She was also assistant medical director for cancer care quality and associate director for quality and curriculum for Stanford's oncology fellowship program. In 2015, she was selected to participate in the American Society of Clinical Oncology's Quality Training Program.

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2020 Sep 30. Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. PMID: 32997807.
      View in: PubMed   Mentions: 1     Fields:    
    2. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020 Aug 05; JCO2001364. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D. PMID: 32755482.
      View in: PubMed   Mentions:    Fields:    
    3. Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes. JCO Oncol Pract. 2020 08; 16(8):431-434. Cinar P, Cox J, Kamal A, Bickel K, Krzyzanowska M, Armitage J, Ganti AK, Ward J, Wong S, Lonial S, Bosserman L. PMID: 32463764.
      View in: PubMed   Mentions:
    4. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Netw. 2020 04 15; 1-6. Cinar P, Kubal T, Freifeld A, Mishra A, Shulman L, Bachman J, Fonseca R, Uronis H, Klemanski D, Slusser K, Lunning M, Liu C. PMID: 32294617.
      View in: PubMed   Mentions: 14     Fields:    
    5. Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series. Anticancer Res. 2020 02; 40(2):865-871. Gonzalez A, Walker EJ, Van Loon K, Cinar P, Atreya CE. PMID: 32014930.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2019 12; 42(12):898-902. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. PMID: 31634155.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot Feasibility Stud. 2019; 5:123. Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. PMID: 31720002.
      View in: PubMed   Mentions:
    8. Variation Across the Continuum of Surgical Oncology Care. JAMA Netw Open. 2018 10 05; 1(6):e183035. Wick EC, Cinar P. PMID: 30646213.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 11; 211(5):1010-1019. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. PMID: 30063366.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Chin Clin Oncol. 2017 Jun; 6(3):29. Cinar P, Ko AH. PMID: 28705006.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer Res. 2014 Dec; 34(12):7357-60. Cinar P, Calkins SM, Venook AP, Kelley RK. PMID: 25503172.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2014 Feb; 12(2):167-72. Cinar P, Ko AH. PMID: 24586078.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64. Cinar P, Tempero MA. PMID: 23187854.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    14. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008 Jan 01; 26(1):66-75. Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL, Anton-Culver H. PMID: 18165642.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    Pelin's Networks
    Concepts (82)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑